Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events

The ESL was well tolerated and did not produce significant PBSEs in those who had PBSEs with LEV leading to withdrawal of the drug. Though numbers were small, the findings suggest that ESL could be a treatment option in those who develop PBSEs with LEV and possibly other AEDs.